Olanzapine (Zyprexa Relprevv) vs Paliperidone palmitate (Erzofri)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Paliperidone palmitate (Erzofri)
Marketed by Luye Pharma Group
NCT03751488 · Phase 1 · completed
This randomized, open-label, single-dose Phase 1 study in 48 patients with schizophrenia compared the pharmacokinetics of LY03010 (this product, at 117, 156 and 351 mg) with INVEGA SUSTENNA 156 mg. It measures drug exposure, not clinical efficacy, and no results have been posted.
Next expected readout: December 2027 · NCT07927946 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Paliperidone palmitate (Erzofri) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | —Not reported |
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | —Not reported |
| PANSS response | —Not posted · NCT00088491 | —Not reported |
| PSP, change | —Not posted · NCT00088491 | —Not reported |
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | —Not reported |
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone palmitate (Erzofri)
- —Not reported
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Paliperidone palmitate (Erzofri)
- —Not reported
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone palmitate (Erzofri)
- —Not reported
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Paliperidone palmitate (Erzofri)
- —Not reported
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Paliperidone palmitate (Erzofri)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Paliperidone palmitate (Erzofri): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Olanzapine (Zyprexa Relprevv): 4 of 4 rows · Paliperidone palmitate (Erzofri): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) |
|---|---|
| Dropout rate | 54.9%a NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 9.8%a NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 9.5%a NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Paliperidone palmitate (Erzofri)'s landscape